menu
    • menu
    [{"orgOrder":0,"company":"Hull University Teaching Hospitals NHS Trust","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ambroxol Hydrochloride","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hull University Teaching Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Hull University Teaching Hospitals NHS Trust \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hull University Teaching Hospitals NHS Trust \/ Sanofi"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ambroxol Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ambroxol Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Agyany Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Ambroxol Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Agyany Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Agyany Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Agyany Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Ambroxol Hydrochloride

    Menu

    Ambroxol Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Agyany Pharma

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Agyany Pharma

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            High-Dose Ambroxol in GBA1-Related Parkinson

                            Details : Ambroxol HCl is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 05, 2024

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hull University Teaching Hospitals NHS Trust

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hull University Teaching Hospitals NHS Trust

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.

                            Details : Ambroxol HCl is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cough.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 30, 2018

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Muco...

                            Details : Ambroxol HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 18, 2014

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup ...

                            Details : Ambroxol HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 18, 2014

                            Lead Product(s) : Ambroxol Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth